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Abstract 
Myocardial infarction induced hypertrophy of non-infarcted myocardium, in parallel with interstitial and perivascular fibrosis and a 
decreased capillary density, could increase sensitivity to ischemia. The structural cardiac hanges can be reversed by long-term captopril 
treatment. In the present study, ischemic sensitivity in relation to cardiac perfusion was studied in isolated, perfused hearts of untreated 
and captopril-treated infarcted rats. In chronically (8 weeks) infarcted hearts, maximal vasodilation in response to administered adenosine 
and nitroprusside, as well as to endogenously released vasodilators during reperfusion, was decreased, suggesting impaired cardiac 
perfusion. Ischemic release of purines and lactate was reduced in infarcted hearts, indicating decreased sensitivity to ischemia of the 
remodeled myocardium. Captopril treatment (3-8 weeks post myocardial infarction), which reversed hypertrophy without affecting the 
flow capacity of the coronary vascular bed, restored maximal cardiac perfusion. Ischemic ATP breakdown was not affected by captopril, 
whereas lactate release was even further educed, suggesting alterations towards a more aerobic ATP production. These data indicate that 
despite the reduced maximal cardiac perfusion, the remodeled myocardium of infarcted hearts is less sensitive to ischemia. Reversal of 
hypertrophy by chronic captopril restored maximal cardiac perfusion and led to a better preservation of aerobic ATP production during 
ischemia. 
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1. Introduction 
Cardiac hypertrophy is regarded an independent risk 
factor for cardiovascular mortality (Levy et al., 1990). One 
of the proposed mechanisms i an increased sensitivity to 
ischemia of the hypertrophied myocardium. In rats, con- 
centric but not eccentric hypertrophy is associated with 
enhanced ischemic vulnerability, which could be attributed 
to differences in cardiac perfusion (Harmsen et al., 1994). 
Myocardial infarction evokes compensatory hypertrophy 
of the non-infarcted myocard ium of  a mixed 
eccentric/concentric type, since myocyte dimensions in- 
crease both in width and in length (Anversa et al., 1985). 
The reactive hypertrophy after myocardial infarction is 
accompanied by interstitial (Van Krimpen et al., 1991a) 
and perivascular (Sun et ai., 1994) fibrosis, and a reduction 
in capillary density (Anversa et al., 1985, 1986). These 
changes also occur in concentric hypertrophy, in which an 
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increased sensitivity to ischemia has been reported (Canby 
and Tomanek, 1990). However, information about the 
ischemic vulnerability of the remodeled myocardium post 
myocardial infarction is not available yet. 
Treatment with angiotensin converting enzyme in- 
hibitors has now become a common therapy after myocar- 
dial infarction, since it improves the heart function and 
prognosis of patients (Pfeffer et al., 1992), as well as 
myocardial infarcted rats (Pfeffer et al., 1987; Schoemaker 
et al., 1991). An important mode of action of angiotensin 
converting enzyme inhibitor therapy is its effect on the 
structural changes in surviving myocardium post myocar- 
dial infarction. Captopril treatment prevents or reverses 
cardiac hypertrophy (Pfeffer et al., 1985) and interstitial 
fibrosis (Van Krimpen et al., 1991a) of the spared myo- 
cardium. However, it is still unknown whether these ef- 
fects on remodeling also increase tolerance to ischemia. 
Promising results were obtained with enalapril treatment in 
spontaneously h pertensive rats (Schoemaker et al., 1994). 
In the present study, sensitivity to ischemia in relation 
to cardiac hypertrophy and remodeling, as well as baseline 
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and maximal cardiac perfusion, was investigated in rats 
with chronic myocardial infarction. In parallel, the effects 
of long-term captopril treatment were studied. 
2. Materials and methods 
Male, Wistar rats (270-320 g, Harlan, Zeist, Nether- 
lands) were used in this study. Rats were housed under a 
12-h light/dark cycle with standard rat chow and water 
available ad libitum. Captopril (Squibb, Princeton, NJ, 
USA) treatment (2 g / l  of drinking water; Pfeffer et al., 
1985, 1987) was started 3 weeks after infarction and was 
continued until the end of the experiment, 8 weeks after 
surgery. Since in previous studies no effects of long-term 
captopril treatment on hypertrophy or remodeling parame- 
ters in sham rats could be found (Van Krimpen et al., 
1991b), we only studied effects of treatment on rats with 
myocardial infarction. The experiments were approved by 
the University Ethics Committee for the use of experimen- 
tal animals. 
(d P/d t) and heart rate. Left ventricular end-diastolic pres- 
sure was set to 5 mm Hg by adjusting the balloon volume. 
Coronary flow was measured by an in-line flow-probe 
(Transonic Systems, Ithaca, NY, USA) placed in the tub- 
ing to monitor the flow of buffer passing through the probe 
just before the buffer entered the coronary arteries. After a 
stabilization period of 15 min, maximal coronary flow 
during vasodilation was determined. 0.1 ml of a 10 -2 M 
adenosine solution (Janssen Chimica, Geel, Belgium) was 
injected into the perfusing buffer just before the buffer 
entered the coronary arteries, followed by a re-stabilization 
period, and subsequently 0.1 ml of a 10 -2 M sodium 
nitroprusside solution (Department of Pharmacy, Aca- 
demic Hospital Dijkzigt, Rotterdam, Netherlands) was in- 
jected into the perfusing buffer. These doses were found to 
induce a maximal effect, as determined from dose-re- 
sponse curves obtained in pilot experiments. Coronary 
flow is expressed as absolute values of ml/min, as an 
index for the flow capacity of the coronary vascular bed, 
as well as values corrected for heart weight (mainly myo- 
cytes), representing cardiac perfusion. 
2.1. Surgical preparation 2.3. lschemia nd reperfusion 
Under pentobarbital (60 mg/kg  i.p.) anesthesia, left 
anterior descending coronary artery ligation was performed 
as described in detail elsewhere (Fishbein et al., 1978; 
Pfeffer et al., 1979; Schoemaker tal., 1991). Briefly, after 
the trachea was intubated, an incision was made in the skin 
overlying the 4th intercostal space. The overlying muscles 
were separated and kept aside. The animals were put on 
positive pressure ventilation (frequency 65/min, tidal vol- 
ume 3 ml), and the thoracic cavity was opened by cutting 
the intercostal muscles. The heart was left in situ and a 6-0 
silk suture was looped under the left coronary artery near 
the origin of the pulmonary artery. The suture was tied 
except in sham operation. Ribs were pulled together with 
3-0 silk. Subsequently, the muscles were returned to their 
normal position, and the skin was sutured. 
Perfusion pressure was abruptly lowered to 15 mm Hg. 
In pilot experiments, continued pacing during ischemia 
was often found to induce severe arrhythmia. Therefore, 
during ischemia, hearts were allowed to beat sponta- 
neously. Because of the very low values, coronary flow 
during ischemia was measured by timed collection of 
coronary effluent. During the last minute of ischemia nd 
the first minute of reperfusion, coronary effluent was 
sampled on ice and stored at -80°C until assayed for 
lactate and purines. After 30 min of low-flow ischemia, 
perfusion pressure was reset to 85 mm Hg. Maximal 
coronary flow during reperfusion (reactive vasodilation) 
was determined. 
2.4. Determination ofpurines and lactate 
2.2. Response to coronary vasodilators 
Under pentobarbital nesthesia, the heart was rapidly 
excised and mounted for perfusion with an oxygenated 
Krebs-Henseleit buffer (composition in mM: NaC1 125, 
KCI 4.7, CaCI 2 1.35, NaHCO 3 20, NaHzPO 4 0.4, MgCI 2 
1.0, o-glucose 10; pH = 7.4; 37°C) at a constant pressure 
of 85 mm Hg, using the Langendorff technique. Heart rate 
was kept constant at 350 beats/min by pacing with a 
Grass stimulator (Grass Medical Instruments, Quincy, MA, 
USA). A water-filled latex balloon was inserted into the 
left ventricle via the left atrium, and connected to a 
pressure transducer (Viggo-Spectramed, Oxnard, USA). 
The pressure signal was fed into a 68B09-based preproces- 
sor and an AT compatible microcomputer for on-line 
recording of left ventricular pressure, its first derivative 
The release of purines into the coronary effluent, calcu- 
lated as concentration × flow per heart weight, was used to 
investigate loss of ATP catabolites from the myocytes 
(Schrader et al., 1977; Achterberg et al., 1984). The car- 
diac loss of ATP catabolites during ischemia correlates 
well with myocardial ATP breakdown, as measured with 
[3~p]nuclear magnetic resonance (Harmsen and Seymour, 
1988). The concentration of purines was determined as 
described in detail by Smolenski et al. (1990). Briefly, the 
ATP catabolites uric acid, uracil, cytidine, adenosine, ino- 
sine, hypoxanthine, xanthine and uridine were determined 
by high-performance liquid chromatography on a C~8- 
/xBondapak column (Millipore Waters Co., Milford, MA, 
USA). Coronary effluent (100 /xl) was injected directly 
into the system, eluted with a 15% (v/v)  solution of 
acetonitrile in 150 mM potassium dihydrogen orthophos- 
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phate, containing 150 mM potassium chloride adjusted to 
pH 6.0 with potassium hydroxide. Peaks were monitored 
by absorption at 254 nm. 
The release of lactate into the coronary effluent was 
used as an indicator of the activity of anaerobic glycolysis 
in the cardiomyocyte (Vrobel et al., 1982). Lactate concen- 
tration in coronary effluent was determined as described in 
detail by Marbach and Weil (1967) (reagents, Sigma Diag- 
nostics, Deisenhofen, Germany). Briefly, lactic acid was 
converted by lactate oxidase to pyruvate and H202. In the 
presence of the H20 2 formed, peroxidase catalyzed the 
oxidative condensation of chromogen precursors to pro- 
duce a colored dye with an absorption maximum at 540 
nm. Lactate concentration could be determined, being di- 
rectly proportional to the increase of absorption at 540 nm. 
2.5. Data analysis 
Data are expressed as group means + S.E.M., unless 
indicated otherwise. Only data from infarcted hearts with 
an infarct area comprising the major part of the left 
ventricular free wall were included in the study, since 
smaller infarctions are known to be hemodynamically fully 
compensated (Pfeffer et al., 1979; Schoemaker et al., 
1991). Data were analyzed using one-way analysis of 
variance (ANOVA), followed by a post-hoc t-test (Wallen- 
stein et al., 1980). Differences were considered statistically 
significant if P < 0.05. 
3. Results 
All infarctions were transmural and were located in the 
lateral (free) wall of the left ventricle. Four hearts, two in 
the untreated infarcted group and two in the captopril- 
treated infarcted group, were excluded from analysis be- 
cause only a minor part of the left ventricular free wall 
was infarcted. Results comprise data from 7 sham hearts, 
10 untreated infarcted hearts, and 7 captopril-treated in-
farcted hearts. Heart weight was significantly increased 
after myocardial infarction compared to that of sham-oper- 
ated controls. Captopril treatment reduced the weight of 
infarcted hearts to sham values. Because body weight was 
also found to be decreased in captopril treated rats, the 
ratio of heart weight to body weight was not influenced by 
captopril treatment (Table 1). 
3.1. Coronary vasodilation (Fig. 1) 
Baseline coronary flow was lower in infarcted hearts, 
although this did not reach statistical significance. How- 
ever, cardiac perfusion, coronary flow corrected for heart 
weight, was significantly depressed after myocardial in- 
farction. Captopril treatment did not alter baseline coro- 
nary flow or cardiac perfusion. 
Maximal absolute values for coronary flow, indicating 
Table 1 
Body weight and cardiac weight 
SHAM MI MI + CAP 
BW(g) 417_+13 402_+10 341+1l  ~b 
(g) 1.08 -+ 0.04 1.34 -+ 0.07 a 1.07 + 0.06 b 
HWW/BW(×10 -3) 2.6 4-0.1 3.3 +0.2 a 3.2 4-0.2 a 
MI, untreated infarcted hearts; MI+CAP,  captopril-treated infarcted 
hearts; BW, body weight; HWW, heart wet weight; HWW/BW,  heart 
wet weight to body weight ratio, a Significantly different from sham-op- 
erated rats; b significantly different from untreated infarcted rats. 
the maximal flow capacity of the coronary vascular bed, 
were decreased in infarcted hearts with adenosine but not 
with nitroprusside. When corrected for heart weight, maxi- 
mal cardiac perfusion with both vasodilators was reduced. 
Chronic captopril treatment restored maximal cardiac per- 
fusion in infarcted hearts. 
Reactive vasodilation during reperfusion resulted in 
maximal values for cardiac perfusion similar to those 
obtained after administration f exogenous vasodilators for 
all groups (Table 2). Maximal reactive vasodilation was 
depressed in infarcted hearts, but was restored by captopril 
treatment. 
3.2. Left ventricular function during ischemia nd reperfu- 
sion (Fig. 2) 
Under baseline conditions, left ventricular systolic pres- 
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Fig. 1. Coronary flow (absolute values, upper panel) and coronary flow 
corrected for cardiac wet weight (cardiac perfuSion, lower panel), at 
baseline and after intracoronary bolus injection of adenosine and nitro- 
prusside. Open bars: sham hearts, black bars: untreated infarcted hearts 
(M1), hatched bars: captopril-treated infarcted hearts (MI + CAP). a Sig- 
nificantly different from sham values, b significantly different from un- 
treated infarcted hearts. 
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Table 2 
Peak cardiac perfusion after vasodilators and during reperfusion 
Maximal cardiac perfusion (ml/min.  g) 
SHAM M[ MI+CAP 
Adenosine 25.0+2.0 16.7_+ 1.2 a 24.3_+ 1.5 ~ 
Nitroprusside 25.3-+2.3 18.2_+ 1.2 a 23.5-+ 1.2 b 
Reperfusion 23.5 + 1.2 15.2_+ 1.1 a 20.8 + 1.0 ~ 
Maximal cardiac perfusion (ml /min.g)  after intracoronary injection of 
adenosine, of nitroprusside, and during reperfusion after 30 min of 
low-flow ischemia. MI, untreated infarcted hearts; MI + CAP, captopril- 
treated infarcted hearts, a Significantly different from sham hearts; b sig- 
nificantly different from untreated infarcted hearts. 
tion (53 _ 7 vs. 79 + 12 mm Hg in shams). Furthermore, 
contractility and relaxation were depressed in infarcted 
hearts, indicated by a decreased peak velocity of pressure 
change ( + (d P/d t)ma x and - (d P/d t)ma x). Chronic cap- 
topril treatment did not significantly alter these parameters 
(Fig. 2). 
Lowering the perfusion pressure to 15 mm Hg resulted 
in low-flow ischemia (0.86 _+ 0.05, 0.78 _+ 0.07 and 0.78 
_+ 0.07 ml/min • g, in sham, untreated infarcted and capto- 
pril-treated infarcted hearts, respectively, at the beginning 
of the ischemic period). Resetting the perfusion pressure to 
85 mm Hg induced reactive vasodilation with a maximum 
after approximately 1 min. Captopril restored the reduced 
maximal postischemic perfusion in infarcted hearts (Table 
2), but did not influence perfusion at other time points. 
Ischemia caused a marked bradycardia (heart rate 65 + 
19, 45 + 5 and 53 +_ 13 min -~ in sham, untreated infarcted 
and captopril-treated infarcted hearts, respectively, after 30 
min of ischemia). Reperfusion quickly restored heart rate 
to baseline values (281 + 29, 298_+ 17 and 277 +_ 27 
min-~ in sham, untreated infarcted and captopril-treated 
infarcted hearts, respectively, after 1 min of reperfusion). 
Furthermore, a profound depression of left ventricular 
function was present during ischemia. Pressure-rate prod- 
uct (left ventricular systolic pressure × heart rate), as an 
index of cardiac work, averaged 1710 _+ 166 mm Hg - s -  
in sham hearts during ischemia nd was significantly lower 
in infarcted hearts (953 _+ 171 and 825 _+ 218 mm Hg- s 
in untreated and captopril-treated hearts, respectively). 
During reperfusion, parameters for left ventricular function 
were restored to baseline values. +(dP/dt)ma x was signif- 
icantly lower in infarcted hearts compared to sham hearts 
during the entire experiment, while these differences for 
-(dP/dt)ma x and systolic pressure only reached statisti- 
cal significance at baseline and during reperfusion. Capto- 
pril therapy did not significantly alter in vitro functional 
parameters in infarcted hearts at any timepoint. 
3.3. Cardiac release of purines and lactate (Fig. 3) 
During the last minute of ischemia, the concentration of
purines in coronary effluent was significantly lower in 
infarcted hearts compared to sham hearts, and even further 
reduced after captopril treatment (Table 3). Since coronary 
flow was not similar for the experimental groups, purine 
release was calculated as concentration times flow per 
heart weight. Cardiac release of purines was lower in 
infarcted hearts than in sham hearts, but was not affected 
by captopril treatment. Similarly, during the first minute of 
reperfusion, release of purines was significantly lower in 
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Fig. 2. Physiological parameters during Langendorff perfusion, at base- 
line, during ischemia nd reperfusion. Open circles: sham hearts, black 
circles: untreated infarcted hearts (MI), triangles: captopril-treated in- 
farcted hearts (MI + CAP). Upper panel: cardiac perfusion, middle panel: 
peak velocity of left ventricle pressure rise during contraction 
(+(dP/dt)max), lower panel: peak velocity of left ventricle pressure 
decline during relaxation ( - (d  P/dt)ma x). a Significantly different from 
sham values, b significantly different from untreated infarcted hearts. 




















Fig. 3. Cardiac release of purines (upper 2 panels) and lactate (lower 2 
panels) into coronary effluent, during ischemia (left panels) and reperfu- 
sion (right panels). Open bars: sham hearts, black bars: untreated in- 
farcted hearts (MI), hatched bars: captopril-treated infarcted hearts (MI + 
CAP). • Significantly different from sham values, b significantly different 
from untreated infarcted hearts. 
Table 3 
Concentrations (p.M) of purines and lactate in coronary effluent 
SHAM MI MI + CAP 
Purines Ischemia 13.1 + 1.1 10.45- 1.1 a 7.3+0.6 a 
Reperfusion 3.1 -t-0.3 3.1 5-0.5 2.2+0.2 
Lactate Ischemia 981 5- 134 941 5- 68 4445- 56 a,b 
Reperfusion 111 5-28 1755-42 1035- 11 
M1, untreated infarcted hearts; MI+CAP, captopril-lxeated infarcted 
hearts; lschemia, last minute of 30 min of ischemia; Reperfusion, first 
minute of reperfusion, a Significantly different from sham hearts; b sig- 
nificantly different from untreated infarcted hearts. 
untreated infarcted hearts compared to sham hearts, and 
not altered by captopril treatment (Fig. 3). 
Lactate concentrations in coronary effluent were com- 
parable in untreated infarcted hearts and sham hearts, but 
significantly reduced in captopril-treated infarcted hearts 
(Table 3). Cardiac release of lactate appeared to be signifi- 
cantly lower in infarcted hearts, and even further educed 
after captopril treatment (Fig. 3). 
4. Discussion 
Hypertrophy and remodeling of the spared myocardium 
after myocardial infarction could increase the sensitivity to 
ischemia of this tissue, and hence the risk of additional 
morbidity, and mortality. In the present study, the sensitiv- 
ity of remodeled, chronically infarcted hearts to acute 
ischemia in relation to cardiac perfusion, and the effects of 
long-term captopril treatment were studied. 
4.1. Maximal vasodilation with adenosine and nitroprus- 
side 
Ischemia evokes release of vasodilatory substances like 
adenosine (Saito et al., 1981) and nitric oxide (Kostic and 
Schrader, 1992). Vascular changes associated with postin- 
farction remodeling, such as perivascular fibrosis (Sun et 
al., 1994), could mechanically restrict vasodilation. To 
investigate this possibility, maximal coronary flow in re- 
sponse to exogenous adenosine, as well as to nitroprusside, 
was measured. 
Maximal coronary flow in response to adenosine, but 
not in response to nitroprusside, was found to be reduced 
in infarcted hearts. These absolute values, not corrected 
for heart weight, represent maximal flow through the 
coronary vascular bed. The observation that vasodilation 
induced by nitroprusside did not differ between infarcted 
hearts and sham hearts implies that the maximal flow 
capacity of the coronary vascular bed is not decreased in
infarcted hearts. In the presence of a permanently occluded 
left descending coronary artery (one of the 3 major coro- 
nary arteries), a maximal flow that is not different from 
maximal flow in sham hearts indicates angiogenesis or 
growth of native vessels of the vascular bed of the remain- 
ing 2 patent coronary arteries. In the present study, only 
measurements of total coronary flow, without evaluation of 
regional distribution, were obtained. Therefore, the flow 
that is actually directed to the non-infarcted part of the left 
ventricle, which would have an increased metabolic de- 
mand to compensate for the loss of contractile tissue in the 
infarcted area, is unknown. Nevertheless, it is clear from 
our observations that the remodeling induced by myocar- 
dial infarction does not cause a mechanical limitation to 
vasodilation. This is in agreement with results from studies 
of experimental hypertension, showing that coronary me- 
dial thickening (not occurring in myocardial infarction 
hearts) rather than perivascular fibrosis is associated with 
decreased maximal vasodilation (Brilla et al., 1991). The 
reduced maximal flow with adenosine would then be 
related to changed pharmacological rather than to struc- 
tural properties of the coronary vascular bed. 
Maximal cardiac perfusion, coronary flow per heart 
weight, however, was decreased for both vasodilators. This 
is in agreement with results from in vivo studies of coro- 
nary reserve in the myocardial infarction rat model (Karam 
et al., 1990). The deficit in the increase of capillary surface 
relative to the increase of cardiomyocyte volume in postin- 
farction cardiac remodeling (Anversa et al., 1986) could be 
responsible for this phenomenon. 
Captopril treatment did not affect baseline coronary 
flow nor cardiac perfusion, suggesting that direct vasodilat- 
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ing effects of captopril can be excluded. The observed 
effects may therefore be attributed to structural changes 
after long-term treatment rather than to direct effects of 
captopril. Captopril treatment in the present study reduced 
heart weight without affecting the maximal flow through 
the coronary vascular bed, and hence restored maximal 
cardiac perfusion. Similar findings have been reported with 
spontaneously hypertensive rats (Canby and Tomanek, 
1989). The observation that regression of hypertrophy by 
captopril is associated with normalization of maximal car- 
diac perfusion, supports the hypothesis that a dispropor- 
tionate growth of myocyte volume relative to cardiac 
vascularization is responsible for the reduced maximal 
cardiac perfusion in myocardial infarction hearts. 
4.2. Vasodilation during reperfusion 
The heart responds to transient ischemia with reactive 
vasodilation due to the release of vasodilatory substances, 
including nitric oxide (Kostic and Schrader, 1992) and 
adenosine (Saito et al., 1981). Maximal coronary flow 
during reperfusion, in the present study, reached values 
similar to those obtained with the vasodilators adminis- 
tered. These data indicate that maximal coronary vasodila- 
tion may indeed occur in vivo after an ischemic episode. 
Similar to the maximal values obtained after administra- 
tion of vasodilators, peak cardiac perfusion during reperfu- 
sion was depressed in myocardial infarction compared to 
sham hearts and was restored after captopril treatment. The 
explanation for these findings may therefore be similar to 
that for the maximal vasodilation seen with the adminis- 
tered vasodilators. 
4.3. Sensitivity to acute ischemia 
Cardiac remodeling due to chronic hypertension can 
increase sensitivity to ischemia (Canby and Tomanek, 
1990; Harmsen et al., 1994). The cardiac remodeling 
induced by pressure overload shows many similarities to 
post myocardial infarction remodeling, including myocyte 
hypertrophy, interstitial and perivascular fibrosis, and re- 
duced capillary density. One of the explanations for en- 
hanced ischemic vulnerability is the increased oxygen 
diffusion distance, caused by myocyte hypertrophy with a 
relatively inadequate increase in capillary surface area. 
This is supported by metabolic adaptions within the myo- 
cytes, including a shift from V~ to V 3 isomyosin (Geenen 
et al., 1989), with a lower ATPase activity, and thus a 
lower oxygen consumption for the same force of contrac- 
tion. In infarcted hearts, the marked epression of the peak 
velocity of the rise in left ventricular pressure, rather than 
the left ventricular pressure per se, indicates a more eco- 
nomical ATP usage. 
Acute ischemia results in cardiomyocyte hypoxia, which 
in turn impairs oxidative phosphorylation (Wilson et al., 
1977), the primary means of ATP production under normal 
conditions (high ATP yield). During ischemia, decreased 
ATP regeneration can finally result in the loss of ATP 
catabolites, purines, from the cell (Schrader et al., 1977). 
In order to preserve intracellular ATP levels during is- 
chemia, anaerobic glycolysis is activated. However, anaer- 
obic ATP production (low ATP yield) is insufficient o 
meet the cellular ATP demand (Hearse, 1979). Moreover, 
during anaerobic glycolysis intracellular pH falls, which 
hampers cell function (Katz, 1973). 
In the present experiments, the ischemic release of ATP 
catabolites from myocardial infarction hearts was lower 
than from sham hearts, which cannot be explained by 
differences in coronary flow or heart weight. The de- 
creased loss of ATP catabolites was also not attributable to
a greater ATP production by anaerobic glycolysis in myo- 
cardial infarction hearts compared to sham hearts, since 
lactate release from infarcted hearts was lower as well. 
Therefore, the explanation for this phenomenon may rather 
lie in the lower ATP consumption in infarcted hearts, 
which would be in concordance with the slower contrac- 
tion in the present study and with the isomyosin shift 
reported by Geenen et al. (1989). Despite the major differ- 
ences in perfusion and ischemic release of ATP catabolites 
and lactate, functional recovery during reperfusion was 
almost complete in all groups, indicating no irreversible 
damage to the heart. 
Although captopril treatment started after 3 weeks in 
infarcted rats has been found to restore in vivo heart 
function (Schoemaker t al., 1991) already after 2 weeks 
of treatment, an effect seen up to 3 months of treatment 
(Pfeffer et al., 1985), in vitro left ventricular function was 
not significantly improved. The discrepancy can probably 
be explained by the measurement of in vitro left ventricu- 
lar function as mechanical parameter of isovolumic on- 
traction at a fixed preload and heart rate, which may not 
correlate well with the in vivo pump capacity of the heart. 
Captopril treatment did not alter the reduction in ATP 
breakdown in infarcted hearts compared to sham hearts, 
but further reduced lactate release. Although angiotensin 
converting enzyme inhibitor treatment has been found to 
reverse the V 1 to V 3 isomyosin shift in infarcted hearts 
(Michel et al., 1988), in vitro cardiac dynamics were not 
changed accordingly by captopril. Thus, like untreated 
infarcted hearts, captopril-treated infarcted hearts probably 
have a lower ATP turnover than sham hearts. Moreover, 
since lactate release in infarcted hearts was even further 
reduced by captopril, aerobic ATP production during acute 
ischemia in infarcted hearts may be preserved longer after 
captopril treatment. It is feasible that the captopril-induced 
reversal of hypertrophy could contribute to a more aerobic 
metabolism during ischemia. By reversing hypertrophy but 
not vessel growth, captopril therapy would reduce the 
oxygen diffusion distance. This is supported by the restora- 
tion of maximal cardiac perfusion by captopril treatment. 
In hypertrophied rat hearts, due to pressure overload, 
chronic captopril therapy restored the capillary density 
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(Canby and Tomanek, 1989) and decreased myocyte sensi- 
tivity to hypoxia (Canby and Tomanek, 1990). 
In conclusion, myocardial infarction-related cardiac re- 
modeling was associated with a decreased maximal cardiac 
perfusion to administered as well as to endogenous va- 
sodilators. However, infarcted hearts were less sensitive to 
an additional acute ischemic period, as indicated by a 
lower cardiac ATP breakdown. Captopril treatment re- 
suited in a restoration of maximal cardiac perfusion. The 
decreased ischemic ATP breakdown in infarcted hearts 
was unaffected by captopril treatment, but was accompa- 
nied by a lower lactate release, suggesting an alteration 
towards a more aerobic ATP production. 
4.4. Clinical implications 
Since myocardial infarction commonly occurs as a com- 
plication of diffuse coronary artery disease, myocardial 
infarction patients will be at risk for additional ischemic 
attacks in the remaining myocardium. The reduced coro- 
nary reserve of cardiac perfusion in infarcted hearts, as 
indicated by reduced maximal cardiac perfusion, may limit 
cardiac function and lead to ischemia during periods of 
increased coronary flow demand, like during stress and 
exercise. Restoration of maximal perfusion with captopril 
may therefore reduce the number of ischemic episodes in 
myocardial infarction patients, and this would be, in addi- 
tion to the hemodynamic improvement, another mecha- 
nism for increased exercise tolerance and improved clini- 
cal outcome. 
Lactate production causes proton accumulation within 
the myocyte, which hampers cellular function in an already 
stressed hemodynamic situation. A reduced ischemic lac- 
tate production in captopril-treated myocardial infarction 
patients may save myocytes from acidosis-induced damage 
(Armiger et al., 1977). 
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